Lexicon Pharmaceuticals I... (LXRX)
NASDAQ: LXRX
· Real-Time Price · USD
0.72
0.06 (8.91%)
At close: Jun 05, 2025, 3:59 PM
0.73
1.65%
After-hours: Jun 05, 2025, 07:58 PM EDT
8.91% (1D)
| Bid | 0.7 |
| Market Cap | 260.11M |
| Revenue (ttm) | 31.21M |
| Net Income (ttm) | -177.3M |
| EPS (ttm) | -0.5 |
| PE Ratio (ttm) | -1.43 |
| Forward PE | -2.03 |
| Analyst | Hold |
| Ask | 0.74 |
| Volume | 7,743,906 |
| Avg. Volume (20D) | 13,954,607 |
| Open | 0.67 |
| Previous Close | 0.66 |
| Day's Range | 0.66 - 0.77 |
| 52-Week Range | 0.28 - 2.45 |
| Beta | 1.01 |
About LXRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LXRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LXRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-15.57%
Lexicon Pharmaceuticals shares are trading lower a...
Unlock content with
Pro Subscription
2 months ago
+64.13%
Lexicon Pharmaceuticals shares are trading higher after the company announced an exclusive license agreement with Novo Nordisk for LX9851.
3 weeks ago · seekingalpha.com
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call TranscriptLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate St...
3 months ago · seekingalpha.com
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call TranscriptLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q4 2024 Earnings Conference Call March 6, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate S...
